Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:41:45.559Z.
Calculation as of: 2026-10-06T15:41:45.559Z.
Quote observation: 2026-10-06T15:40:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869772d5b15fe2f366f7470de3318cdd420f1d22994776f46b79eb6f67ec6a89
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Eupraxia Pharmaceuticals Inc.
Market Cap
$265.83M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.82M
EV/Sales Ratio
1.06x
TTM Avg
0.74x
3Y Avg
0.47x
5Y Avg
0.82x
Market Cap
$264.62M
EV/Sales Ratio
N/A
TTM Avg
495.70x
3Y Avg
495.70x
5Y Avg
495.70x
Market Cap
$264.07M
EV/Sales Ratio
N/A
TTM Avg
8390802.46x
3Y Avg
5153796.41x
5Y Avg
3581310.58x
Market Cap
$271.23M
EV/Sales Ratio
65.66x
TTM Avg
74.23x
3Y Avg
31.36x
5Y Avg
21.18x
Market Cap
$262.11M
EV/Sales Ratio
273.87x
TTM Avg
543.80x
3Y Avg
374.50x
5Y Avg
374.50x
Market Cap
$260.03M
EV/Sales Ratio
10.63x
TTM Avg
42.40x
3Y Avg
29706.49x
5Y Avg
21359.19x
Market Cap
$258.56M
EV/Sales Ratio
2.02x
TTM Avg
1.60x
3Y Avg
1.66x
5Y Avg
1.91x
Market Cap
$254.41M
EV/Sales Ratio
N/A
TTM Avg
0.88x
3Y Avg
37.95x
5Y Avg
73.84x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $265.83M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $267.82M | 1.06x | 0.74x | 0.47x | 0.82x |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | N/A | 495.70x | 495.70x | 495.70x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.07M | N/A | 8390802.46x | 5153796.41x | 3581310.58x |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.23M | 65.66x | 74.23x | 31.36x | 21.18x |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | 273.87x | 543.80x | 374.50x | 374.50x |
| AC Immune S.A. (ACIU)vs › | $260.03M | 10.63x | 42.40x | 29706.49x | 21359.19x |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.56M | 2.02x | 1.60x | 1.66x | 1.91x |
| Century Therapeutics, Inc. (IPSC)vs › | $254.41M | N/A | 0.88x | 37.95x | 73.84x |
| Fate Therapeutics, Inc. (FATE)vs › | $278.58M | 49.58x | 36.37x | 26.31x | 30.77x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
